Takeda’s TAKHZYRO approved by EC for pediatric hereditary angioedema
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission's approval of TAKHZYRO (lanadelumab) for routine prevention in ... Read More